The last day of the Congress and time to take stock. Kell Morten Myhr summarised the field of multiple sclerosis (MS), which received 205 abstracts. Professor Myhr started his highlights with papers by Persson et al from Lexington reporting longitudinal observational survival data in MS and Stahmann et al from Hanover who reported variable rates of starting disease-modifying therapy. Professor Myhr considered that these papers together pointed toward a need to start MS therapy early. Prognostic blood biomarkers were then considered with vitamin D shown to predict long-term disability (Wesnes et al, Trondheim), whilst neurofilament light chain was associated with development of cognitive impairment in secondary progressive MS (Kuhle et al, Basel).
